Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Moderna, Inc.NASDAQ: MRNA

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income turns positive

Q3 FY2026 net income was $162M, compared with -$200M a year earlier. Trailing-twelve-month net income was -$2.79B.

Context

  • Net income amounted to 145.2% of revenue in FY2025, up 33.8 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 14 analysts of -$2.89B (+2.4%) for the fiscal year ending Dec 2026, a step up from the -20.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$162M+120.7% QoQ
Last fiscal yearDec 2025
-$2.82B-20.8% YoY
LTMSep 2026
-$2.79B-10.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+181.0%+8.4%-172.6 pp
1 year-20.8%+2.4%+23.2 pp
3-year CAGR—-27.8%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(2.82B) USD
Year-over-year change
+20.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.5% is the 6th highest of 10, against a peer median of +15.4%.
  • Net income amounts to 110.5% of revenue for MRNA, versus a peer median of 64.7%.
MRNA Competitors
Net Income for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
MRNAModerna, Inc.LTM Sep 2026$2.79B USD-10.5%—110.5%
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
PCVXVaxcyte, Inc.LTM Jun 2026$1.38B USD+152.9%+50.8%—
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M USD-23.4%—676.0%
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
NVAXNovavax, Inc.LTM Mar 2026$87.84M USD-118.3%—14.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$84.93M USD-12.0%-32.8%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
Peer median (excluding MRNA) —+15.4%-7.0%64.7%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Depreciation & Amortization232M348M621M189M215M
Deferred Income Tax(318M)(559M)828M00
Stock-Based Compensation142M226M305M429M483M
Change in Working Capital1.31B(3.46B)(139M)(78M)254M
Accounts Receivables(1.78B)1.79B493M534M156M
Inventory(1.39B)492M747M83M(34M)
Accounts Payables204M240M13M(69M)(92M)
Other Working Capital4.28B(5.98B)(1.39B)(626M)224M
Other Non-Cash Items54M59M(19M)17M(3M)
Operating Cash Flow13.62B4.98B(3.12B)(3B)(1.87B)
Capital Expenditures(284M)(400M)(707M)(1.05B)(192M)
Acquisitions (Net)00(85M)00
Purchases of Investments(12.65B)(11.44B)(3.78B)(6.53B)(5.77B)
Sales of Investments4.44B6.7B8.78B9.53B7.92B
Other Investing Activities(30M)(40M)00(10M)
Investing Cash Flow(8.52B)(5.18B)4.21B1.95B1.95B
Debt Repayment(140M)(184M)(270M)(10M)539M
Common Stock Issued124M65M46M66M35M
Common Stock Repurchased(857M)(3.33B)(1.15B)00
Dividends Paid00000
Other Financing Activities000019M
Financing Cash Flow(873M)(3.45B)(1.38B)56M593M
Effect of Forex Changes00002M
Net Change in Cash4.22B(3.64B)(289M)(999M)668M
Free Cash Flow13.34B4.58B(3.83B)(4.06B)(2.07B)

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.